Top

Archives of Gynecology and Obstetrics

Published in:

01-10-2012 | General Gynecology

Effect of mifepristone on COX-2 both in eutopic and ectopic endometrium in mouse endometriotic model

Authors: Xiujuan Li, Yanyan Bao, Peng Fang, Yaping Chen, Zhongdong Qiao

Published in: Archives of Gynecology and Obstetrics | Issue 4/2012

Abstract

Objective

To study the influence of mifepristone on the expression of cyclooxygenase 2 (COX-2) protein and COX-2 mRNA and then to evaluate the mechanism.

Methods

After the establishment of 30 mice endometriosis models, the mice were randomly divided into six groups with 5 mice each group and assigned to experimental and control groups of 1-, 4- and 6-week circle according to whether mifepristone (0.13 mg d⁻¹) was taken or not. Small animal optical imaging system was used to detect the fluorescent intensity of the ectopic tissue. Reverse transcript-polymerase chain reaction and western blot was used to examine COX-2 protein and COX-2 mRNA expression. ELISA was used to examine concentration of PGE₂ in serum.

Result(s)

Mifepristone could not affect the fluorescent intensity of the ectopic endometrium after it was taken 1, 4, and 6 (P > 0.05). However, it could decrease the transcription of COX-2 mRNA in the 1 and 4 week groups (P < 0.05), while the difference in the 6 week group was not significant (P > 0.05). It could decrease the expression of COX-2 protein after it was taken 4 and 6 weeks (P < 0.05). The serous PGE₂ in the trial groups was lower than that in the control groups, but the difference was not significant (P > 0.05).

Conclusion(s)

This study showed that mifepristone could not affect the size of the ectopic endometrium, but it could decrease the transcription of COX-2 gene and then reduce the expression of COX-2 protein and its product PGE₂ which is an important factor which mediate pain. This maybe another mechanism that mifepristone takes effect through anti-inflammatory path.

Lampe L (2009) Endometriosis. Orv Hetil 150(6):245–250PubMedCrossRef

Song JY, Peter R, Robert M, Frank M, Ian SF (1996) Uterus and endometrium: effect of high dose progestogens on white cells and necrosis in human endometrium. Hum Reprod 11(8):1713–1718PubMedCrossRef

Benagiano G, Bastianelli C, Farris M (2008) Selective progesterone receptor modulators 2: use in reproductive medicine. Expert Opin Pharmacother 9(14):2473–2485PubMedCrossRef

Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS (1996) Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 65(1):23–28PubMed

Baird DT, Brown A, Critchleym HOD, Williams AR, Lin S, Cheng L (2003) Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 18(1):61–68PubMedCrossRef

Jiang J, Wu RF, Wang ZH, Sun HC, Xu Z, Xiu HM (2002) Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 77(5):995–1000PubMedCrossRef

Hirata T, Osuga Y, Yoshino O, Hirota Y, Harada M, Takemura Y, Morimoto C, Koga K, Yano T, Tsutsumi O, Taketani Y (2005) Development of an experimental model of endometriosis using mice that ubiquitously express green fluorescent protein. Hum Reprod 20(8):2092–2096PubMedCrossRef

Ota H, Igarashi S, Sasaki M, Tanaka T (2001) Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 16(3):561–566PubMedCrossRef

Wu MH, Wang CA, Lin CC, Chen LC, Chang WC, Tsai SJ (2005) Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab 90(1):286–295PubMedCrossRef

10.

Tamura M, Deb S, Sebastian S, Okamura K, Bulun SE (2004) Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril 81(5):1351–1356PubMedCrossRef

11.

Li J, Lu Y, Ma D (2002) Cyclooxyenase-2 expression in endometrium carcinoma. Zhonghua Fu Chan Ke Za Zhi 37(7):408–410PubMed

12.

Chishima F, Hayakawa S, Sugita K, Kinukawa N, Aleemuzzaman S, Nemoto N, Yamamoto T, Honda M (2002) Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 48(1):50–56PubMedCrossRef

13.

Chishima F, Hayakawa S, Hirata Y, Nagai N, Kanaeda T, Tsubata K, Satoh K (2000) Peritoneal and peripheral B-1-cell populations in patients with endometriosis. J Obstet Gynaecol Res 26(2):141–149PubMedCrossRef

14.

Attar E, Bulun SE (2006) Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 12(1):49–56PubMedCrossRef

15.

Bulun SE, Zeitoun KM, Takayama K, Sasano H (2000) Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance. J Mol Endocrinol 25(1):35–42PubMedCrossRef

16.

Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, Johns A, Meng L, Putman M, Carr B, Bulun SE (1998) Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 83(12):4474–4480PubMedCrossRef

17.

Osteen KG, Bruner KL, Sharpe-Timms KL (1996) Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Semin Reprod Endocrinol 14(3):247–255PubMedCrossRef

18.

Dassen H, Punyadeera C, Kamps R, Delvoux B, Van Langendonckt A, Donnez J, Husen B, Thole H, Dunselman G, Groothuis P (2007) Estrogen metabolizing enzymes in endometrium and endometriosis. Hum Reprod 22(12):3148–3158PubMedCrossRef

19.

Wu Y, Guo SW (2006) Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 62(4):193–205PubMedCrossRef

20.

Mei L, Bao J, Tang L, Zhang C, Wang H, Sun L, Ma G, Huang L, Yang J, Zhang L, Liu K, Song C, Sun H (2010) A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies. Eur J Pharm Sci 39(5):421–427PubMedCrossRef

21.

Guo SW, Liu M, Shen F, Liu X (2011) Use of mifepristone to treat endometriosis: a review of clinical trials and trial-like studies conducted in China. Women Health (Lond Engl) 7(1):51–70CrossRef

22.

Kettel LM, Murphy AA, Morales AJ, Yen SS (1998) Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 178(6):1151–1156PubMedCrossRef

Title: Effect of mifepristone on COX-2 both in eutopic and ectopic endometrium in mouse endometriotic model
Authors: Xiujuan Li
Yanyan Bao
Peng Fang
Yaping Chen
Zhongdong Qiao
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 4/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2379-2

At a glance: The STEP trials

Springer Medicine

Effect of mifepristone on COX-2 both in eutopic and ectopic endometrium in mouse endometriotic model

Abstract

Objective

Methods

Result(s)

Conclusion(s)

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Result(s)

Conclusion(s)

Please log in to get access to this content

Other articles of this Issue 4/2012

Women with one ovary in assisted reproduction technologies: a review of the literature

A large retroperitoneal cystic venous malformation mimicking bilateral ovarian cystic tumors

Sialic acid levels in the blood in pregnant women with impaired glucose tolerance test

Concurrent endometrial adenocarcinoma and an early pregnancy loss

Predictive model for spontaneous preterm labor among pregnant women with contractions and intact amniotic membranes

A randomized controlled trial for cervical priming using vaginal misoprostol prior to hysteroscopy in women who have only undergone cesarean section